Bank of New York Mellon
HLVX

Bank of New York Mellon’s HilleVax HLVX Stock Holding History

Bank of New York Mellon’s Portfolio HLVX Stock Details HLVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-72,690
Closed -$105K – 4192
2025
Q1 		$105K Sell
72,690
-70
-0.1% -$129 ﹤0.01% 3995
2024
Q4 		$151K Hold
72,760
– – ﹤0.01% 3995
2024
Q3 		$128K Sell
72,760
-21,105
-22% -$54.1K ﹤0.01% 3982
2024
Q2 		$1.36M Buy
93,865
+24,410
+35% +$335K ﹤0.01% 3019
2024
Q1 		$1.16M Sell
69,455
-4,181
-6% -$66.9K ﹤0.01% 3073
2023
Q4 		$1.18M Buy
73,636
+11,078
+18% +$147K ﹤0.01% 3104
2023
Q3 		$841K Buy
62,558
+125
+0.2% +$1.76K ﹤0.01% 3260
2023
Q2 		$1.07M Buy
62,433
+14,378
+30% +$223K ﹤0.01% 3159
2023
Q1 		$794K Sell
48,055
-1,866
-4% -$29.9K ﹤0.01% 3238
2022
Q4 		$835K Buy
49,921
+8,411
+20% +$152K ﹤0.01% 3282
2022
Q3 		$710K Buy
41,510
+9,966
+32% +$145K ﹤0.01% 3380
2022
Q2 		$344K Buy
+31,544
New +$375K ﹤0.01% 3807

Other funds holding HLVX

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
LMC
Lightspeed Management Company Menlo Park, California $988M AUM 7.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Bank of New York Mellon's HLVX Position: Q2 2025 in Review

Bank of New York Mellon sold out of HilleVax (HLVX) in Q2 2025, closing a stake of 72,690 shares — an estimated $105K sold.

Bank of New York Mellon first reported a position in HLVX in Q2 2022 and held it in 12 quarters. The position peaked at $1.36M in Q2 2024. 74 funds tracked by Wall St. Rank hold HLVX as of Q2 2025.

  • Bank of New York Mellon reported no remaining HilleVax position as of Q2 2025 after selling out during the quarter.
  • Bank of New York Mellon sold 72,690 HilleVax shares in Q2 2025, an estimated $105K.
  • Bank of New York Mellon first reported a position in HilleVax in Q2 2022 and held it in 12 quarters.
  • Bank of New York Mellon's HilleVax position peaked at $1.36M in Q2 2024.
  • 74 funds tracked by Wall St. Rank held HilleVax as of Q2 2025.

Based on Bank of New York Mellon's 13F filing for Q2 2025, filed 5 Aug 2025.